SynthesisBMC cancer2007
Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Synthesis in BMC cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A Multi-Center Structural Equation Modeling Approach to Investigate Interpersonal Violence Screening for Public Health Promotion.Frontiers in public health · 2021Article
- Non-High-Risk Neuroblastoma: Classification and Achievements in Therapy.Children (Basel, Switzerland) · 2019Article
- Angiogenesis and evading immune destruction are the main related transcriptomic characteristics to the invasive process of oral tongue cancer.Scientific reports · 2018Article
- Integrating and extending cohort studies: lessons from the eXtending Treatments, Education and Networks in Depression (xTEND) study.BMC medical research methodology · 2013Article
- Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- High genomic instability predicts survival in metastatic high-risk neuroblastoma.Neoplasia (New York, N.Y.) · 2012Article
- Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.BMC bioinformatics · 2012Article
- Article
- A 6-gene signature identifies four molecular subgroups of neuroblastoma.Cancer cell international · 2011Article
- Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing.PloS one · 2011Article
- 2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells.Cancer biology & therapy · 2010Article
- Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases.Brain pathology (Zurich, Switzerland) · 2010Article
- Identification of multiple hypoxia signatures in neuroblastoma cell lines by l1-l2 regularization and data reduction.Journal of biomedicine & biotechnology · 2010Article
- Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma.BMC cancer · 2009Article
- Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes.BMC medical genomics · 2009Article
- Plasma midkine level is a prognostic factor for human neuroblastoma.Cancer science · 2008Article
- Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroblastoma patients show heterogeneous clinical courses ranging from life-threatening progression to spontaneous regression. Recently, gene expression profiles of neuroblastoma tumours were associated with clinically different phenotypes. However, such data is still rare for important patient subgroups, such as patients with MYCN non-amplified advanced stage disease. Prediction of the individual course of disease and optimal therapy selection in this cohort is challenging. Additional research effort is needed to describe the patterns of gene expression in this cohort and to identify reliable prognostic markers for this subset of patients.
methodsWe combined gene expression data from two studies in a meta-analysis in order to investigate differences in gene expression of advanced stage (3 or 4) tumours without MYCN amplification that show contrasting outcomes (alive or dead) at five years after initial diagnosis. In addition, a predictive model for outcome was generated. Gene expression profiles from 66 patients were included from two studies using different microarray platforms.
resultsIn the combined data set, 72 genes were identified as differentially expressed by meta-analysis at a false discovery rate (FDR) of 8.33%. Meta-analysis detected 34 differentially expressed genes that were not found as significant in either single study. Outcome prediction based on data of both studies resulted in a predictive accuracy of 77%. Moreover, the genes that were differentially expressed in subgroups of advanced stage patients without MYCN amplification accurately separated MYCN amplified tumours from low stage tumours without MYCN amplification.
conclusionOur findings support the hypothesis that neuroblastoma consists of two biologically distinct subgroups that differ by characteristic gene expression patterns, which are associated with divergent clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.